Free Trial
NYSE:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

NovaBay Pharmaceuticals logo
$0.53 +0.03 (+5.12%)
(As of 12/20/2024 05:31 PM ET)

About NovaBay Pharmaceuticals Stock (NYSE:NBY)

Key Stats

Today's Range
$0.50
$0.53
50-Day Range
$0.49
$0.78
52-Week Range
$0.36
$9.10
Volume
580,562 shs
Average Volume
903,055 shs
Market Capitalization
$2.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.85
Consensus Rating
Buy

Company Overview

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NovaBay Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
29th Percentile Overall Score

NBY MarketRank™: 

NovaBay Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NovaBay Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NovaBay Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about NovaBay Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.95) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NovaBay Pharmaceuticals has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for NBY.
  • Dividend Yield

    NovaBay Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    NovaBay Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NBY.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for NovaBay Pharmaceuticals this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    4 people have added NovaBay Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.10% of the stock of NovaBay Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 23.25% of the stock of NovaBay Pharmaceuticals is held by institutions.

  • Read more about NovaBay Pharmaceuticals' insider trading history.
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NBY Stock News Headlines

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
NovaBay Pharmaceuticals To Sell Assets Of Its Avenova Brand - Quick Facts
See More Headlines

NBY Stock Analysis - Frequently Asked Questions

NovaBay Pharmaceuticals' stock was trading at $7.14 on January 1st, 2024. Since then, NBY shares have decreased by 92.6% and is now trading at $0.5299.
View the best growth stocks for 2024 here
.

NovaBay Pharmaceuticals's stock reverse split on the morning of Friday, May 31st 2024. The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN).

Company Calendar

Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$0.85
High Stock Price Target
$0.85
Low Stock Price Target
$0.85
Potential Upside/Downside
+60.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,640,000.00
Net Margins
-102.72%
Pretax Margin
-99.12%

Debt

Sales & Book Value

Annual Sales
$13.84 million
Book Value
$4.25 per share

Miscellaneous

Free Float
4,903,000
Market Cap
$2.60 million
Optionable
Not Optionable
Beta
0.69
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NYSE:NBY) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners